Michael Overman, MD
Enriched profileProfessor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine; Associate Vice President of Research, MD Anderson Cancer Network · The University of Texas MD Anderson Cancer Center
Michael Overman is Professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine; Associate Vice President of Research, MD Anderson Cancer Network at The University of Texas MD Anderson Cancer Center. OpenAlex indexes 1,076 publications with 32,085 citations (h-index 79); ClinicalTrials.gov lists 14 registered studies with this person as an investigator.
Data verified 16 Oct 2026
Overview
Updated 16 Oct 2026
Michael J. Overman, MD, is Professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, Department of Gastrointestinal Medical Oncology. The public record shows 1,076 publications with 32,085 citations (h-index 79), centered on Colorectal Cancer Treatments and Studies, Genetic factors in colorectal cancer, Cancer Genomics and Diagnostics. It also documents an investigator role on 14 registered clinical trials, industry payments reported by 23 companies, 3 NIH-funded awards (2016–2024).
- Most recent indexed publication: 2026 · The oncologist
- Top research focus: Colorectal Cancer Treatments and Studies
- 14 registered trials on ClinicalTrials.gov
- Open Payments reporting from 23 companies
Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 41 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 299.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 16 Oct 2026
Listed as an investigator on 14 registered studies on ClinicalTrials.gov. The most recent:
- The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer
Sponsor: M.D. Anderson Cancer Center
- Pevonedistat and Pembrolizumab for the Treatment of dMMR/MSI-H Metastatic or Locally Advanced Unresectable Solid Tumor
Sponsor: M.D. Anderson Cancer Center
Industry payments
Updated 16 Oct 2026
23 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- E.R. Squibb & Sons, L.L.C.Program year202515 payments$14,200openpaymentsdata.cms.gov ↗
- Exelixis Inc.Program year202511 payments
- Takeda Pharmaceuticals U.S.A., Inc.Program year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
53.8%Serotonin-3 Receptor Antagonist53.8%Ondansetron Hcl100%Part D<11 patientsSensory organs
46.2%Corticosteroid46.2%Dexamethasone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 16 Oct 2026
3 NIH research awards on record, funded 2016–2024 per NIH RePORTER. The latest:
- A technological approach for performance status assessment in advanced cancer patients
University of Tx Md Anderson Can Ctr
FY2024$546,557R01CA243554 - A technological approach for performance status assessment in advanced cancer patients
University of Tx Md Anderson Can Ctr
FY2023$559,111R01CA243554 - Project 1: Personalized Adjuvant Immunotherapy for High-risk Colorectal Cancer.
University of Tx Md Anderson Can Ctr
FY2023$332,973P50CA221707
Congress activity
Updated 16 Oct 2026
333 congress contributions (2004–2025) across AACR, ASCO, ASH, ASTRO, ESMO, SABCS per OpenAlex. The most recent:
- Abstract B076: Clinical and Molecular Characteristics of <i>KRASQ61</i> Mutated Pancreatic Cancer and Other Gastrointestinal Malignancies
AACR (meeting unresolved)
AACR2025Co-author - A phase I trial of binimetinib plus hydroxychloroquine inpatients with previously treated metastatic pancreatic cancer.
ASCO Annual Meeting
ASCO2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 16 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Prognosis and treatment response stratification according to loss of proofreading (LOP) POLE variants.
Journal for immunotherapy of cancer
Article2025 - Phase II Trial of TAS-102 in Colorectal Cancer Patients With Circulating Tumor DNA-Defined Minimal Residual Disease After Adjuvant Therapy: INTERCEPT-TT.
JCO precision oncology
Clinical Trial2025
Most-cited works
by citation count (OpenAlex)Network
Updated 16 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 16 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/michael-overman-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - X / Twitter
x.com/michael_overman
Mentions by others
where others cite or feature them- X / Twitter
x.com/MDAndersonNews/status/1916697696284578224
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 16 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →faculty.mdanderson.org ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- Past-Chair
Executive Committee of the Medical Staff (ECMS), MD Anderson
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗ - NCCN Guidelines Panel Member
Colon/Rectal/Anal/Small Bowel Cancers Committee
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗ - Member
ASCO, ESMO, SITC, SWOG, College of American Pathologists
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
Media & interviews
press, podcasts and appearances- Recurring video/interview contributor
OncLive (multiple pieces on colorectal cancer, immunotherapy, molecular testing, nonoperative GI cancer management)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗ - Author/contributor
Targeted Oncology (GI cancer immunotherapy and biomarkers coverage)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →targetedonc.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center
Eric Van Cutsem, MD, PhD
University Hospitals Leuven (UZ Leuven)
Josep Tabernero, MD, PhD
Vall d'Hebron Institute of Oncology (VHIO)
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Charles Fuchs, MD, MPH
Tubulis GmbH